

BIOPHARMACEUTICS MODELING AND SIMULATIONS

BIOPHARMACEUTICS MODELING AND SIMULATIONS

Theory, Practice, Methods,
and Applications

KIYOHICO SUGANO

Asahi Kasei Pharma Corp.
Shizuoka, Japan



A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2012 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey
Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Sugano, Kiyohiko.

Biopharmaceutics modeling and simulations : theory, practice, methods,
and applications / Kiyohiko Sugano.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-118-02868-1 (cloth)

I. Title.

[DNLM: 1. Biopharmaceutics—methods. 2. Computer Simulation. 3. Drug
Compounding—methods. 4. Models, Theoretical. QV 38]

615.7—dc23

2012007296

Printed in the United States of America

ISBN: 9781118028681

10 9 8 7 6 5 4 3 2 1

To Hitomi

CONTENTS

PREFACE	xxv
LIST OF ABBREVIATIONS	xxix
1 INTRODUCTION	1
1.1 An Illustrative Description of Oral Drug Absorption: The Whole Story	1
1.2 Three Regimes of Oral Drug Absorption	2
1.3 Physiology of the Stomach, Small Intestine, and Colon	5
1.4 Drug and API Form	6
1.4.1 Undissociable and Free Acid Drugs	6
1.4.2 Free Base Drugs	6
1.4.3 Salt Form Cases	6
1.5 The Concept of Mechanistic Modeling	7
References	8
2 THEORETICAL FRAMEWORK I: SOLUBILITY	10
2.1 Definition of Concentration	10
2.1.1 Total Concentration	11
2.1.2 Dissolved Drug Concentration	11
2.1.3 Effective Concentration	12
2.2 Acid–Base and Bile-Micelle-Binding Equilibriums	13
	vii

2.2.1	Monoprotic Acid and Base	14
2.2.2	Multivalent Cases	16
2.2.3	Bile-Micelle Partitioning	17
2.2.4	Modified Henderson–Hasselbalch Equation	18
2.2.5	K_{bm} from $\text{Log } P_{\text{oct}}$	19
2.3	Equilibrium Solubility	19
2.3.1	Definition of Equilibrium Solubility	19
2.3.2	pH–Solubility Profile (pH-Controlled Region)	21
2.3.3	Solubility in a Biorelevant Media with Bile Micelles (pH-Controlled Region)	23
2.3.4	Estimation of Unbound Fraction from the Solubilities with and without Bile Micelles	25
2.3.5	Common Ionic Effect	25
2.3.6	Important Conclusion from the pH–Equilibrium Solubility Profile Theory	27
2.3.7	Yalkowsky’s General Solubility Equation	27
2.3.8	Solubility Increase by Converting to an Amorphous Form	29
2.3.9	Solubility Increase by Particle Size Reduction (Nanoparticles)	30
2.3.10	Cocrystal	31
	References	31

3 THEORETICAL FRAMEWORK II: DISSOLUTION 33

3.1	Diffusion Coefficient	34
3.1.1	Monomer	34
3.1.2	Bile Micelles	35
3.1.3	Effective Diffusion Coefficient	36
3.2	Dissolution and Particle Growth	36
3.2.1	Mass Transfer Equations: Pharmaceutical Science Versus Fluid Dynamics	37
3.2.2	Dissolution Equation with a Lump Sum Dissolution Rate Coefficient (k_{diss})	38
3.2.3	Particle Size and Surface Area	39
	3.2.3.1 <i>Monodispersed Particles</i>	39
	3.2.3.2 <i>Polydispersed Particles</i>	41
3.2.4	Diffusion Layer Thickness I: Fluid Dynamic Model	41
	3.2.4.1 <i>Reynolds and Sherwood Numbers</i>	42
	3.2.4.2 <i>Disk (Levich Equation)</i>	45
	3.2.4.3 <i>Tube (Graetz Problem)</i>	45

3.2.4.4	<i>Particle Fixed to Space (Ranz–Marshall Equation)</i>	46
3.2.4.5	<i>Floating Particle</i>	47
3.2.4.6	<i>Nonspherical Particle</i>	49
3.2.4.7	<i>Minimum Agitation Speed for Complete Suspension</i>	51
3.2.4.8	<i>Other Factors</i>	52
3.2.5	Diffusion Layer Thickness II: Empirical Models for Particles	52
3.2.6	Solid Surface pH and Solubility	53
3.3	Nucleation	56
3.3.1	General Description of Nucleation and Precipitation Process	56
3.3.2	Classical Nucleation Theory	57
3.3.2.1	<i>Concept of Classical Nucleation Theory</i>	58
3.3.2.2	<i>Mathematical Expressions</i>	58
3.3.3	Application of a Nucleation Theory for Biopharmaceutical Modeling	61
	References	61
4	THEORETICAL FRAMEWORK III: BIOLOGICAL MEMBRANE PERMEATION	64
4.1	Overall Scheme	64
4.2	General Permeation Equation	66
4.3	Permeation Rate Constant, Permeation Clearance, and Permeability	66
4.4	Intestinal Tube Flatness and Permeation Parameters	68
4.5	Effective Concentration for Intestinal Membrane Permeability	70
4.5.1	Effective Concentration for Unstirred Water Layer Permeation	70
4.5.2	Effective Concentration for Epithelial Membrane Permeation: the Free Fraction Theory	70
4.6	Surface Area Expansion by Plicate and Villi	71
4.7	Unstirred Water Layer Permeability	73
4.7.1	Basic Case	73
4.7.2	Particles in the UWL (Particle Drifting Effect)	74
4.8	Epithelial Membrane Permeability (Passive Processes)	76
4.8.1	Passive Transcellular Membrane Permeability: pH Partition Theory	76

4.8.2	Intrinsic Passive Transcellular Permeability	77
4.8.2.1	<i>Solubility–Diffusion Model</i>	77
4.8.2.2	<i>Flip-Flop Model</i>	79
4.8.2.3	<i>Relationship between $P_{trans,0}$ and $\log P_{oct}$</i>	80
4.8.3	Paracellular Pathway	83
4.8.4	Relationship between $\log D_{oct}$, MW, and Fa%	84
4.9	Enteric Cell Model	84
4.9.1	Definition of P_{app}	86
4.9.2	Enzymatic Reaction: Michaelis–Menten Equation	87
4.9.3	First-Order Case 1: No Transporter and Metabolic Enzymes	88
4.9.4	First-Order Case 2: Efflux Transporter in Apical Membrane	91
4.9.5	Apical Efflux Transporter with K_m and V_{max}	95
4.9.6	Apical Influx Transporter with K_m and V_{max}	100
4.9.7	UWL and Transporter	100
4.9.7.1	<i>No Transporter</i>	101
4.9.7.2	<i>Influx Transporter and UWL</i>	101
4.9.7.3	<i>Efflux Transporter</i>	101
4.10	Gut Wall Metabolism	103
4.10.1	The Q_{gut} Model	104
4.10.2	Simple Fg Models	104
4.10.3	Theoretical Consideration on Fg	104
4.10.3.1	<i>Derivation of the Fg Models</i>	105
4.10.3.2	<i>Derivation of the Anatomical Fg Model</i>	107
4.10.4	Interplay between CYP3A4 and P-gp	108
4.11	Hepatic Metabolism and Excretion	114
	References	115
5	THEORETICAL FRAMEWORK IV: GASTROINTESTINAL TRANSIT MODELS AND INTEGRATION	122
5.1	GI Transit Models	122
5.1.1	One-Compartment Model/Plug Flow Model	122
5.1.2	Plug Flow Model	123
5.1.3	Three-Compartment Model	124
5.1.4	S1I7CX ($X = 1-4$) Compartment Models	124
5.1.5	Convection–Dispersion Model	126
5.1.6	Tapered Tube Model	126

5.2	Time-Dependent Changes of Physiological Parameters	127
5.2.1	Gastric Emptying	127
5.2.2	Water Mass Balance	128
5.2.3	Bile Concentration	129
5.3	Integration 1: Analytical Solutions	129
5.3.1	Dissolution Under Sink Condition	130
5.3.1.1	<i>Monodispersed Particles</i>	130
5.3.1.2	<i>Polydispersed Particles</i>	131
5.3.2	Fraction of a Dose Absorbed (Fa%)	132
5.3.3	Approximate Fa% Analytical Solutions 1: Case-by-Case Solution	133
5.3.3.1	<i>Permeability-Limited Case</i>	134
5.3.3.2	<i>Solubility-Permeability-Limited Case</i>	135
5.3.3.3	<i>Dissolution-Rate-Limited Case</i>	137
5.3.4	Approximate Fa% Analytical Solutions 2: Semi-General Equations	137
5.3.4.1	<i>Sequential First-Order Kinetics of Dissolution and Permeation</i>	137
5.3.4.2	<i>Minimum Fa% Model</i>	138
5.3.5	Approximate Fa% Analytical Solutions 3: Fa_{SS} Equation	139
5.3.5.1	<i>Application Range</i>	140
5.3.5.2	<i>Derivation of Fa Number Equation</i>	140
5.3.5.3	<i>Refinement of the Fa_{SS} Equation</i>	141
5.3.5.4	<i>Advantage of Fa_{SS} Equation</i>	146
5.3.5.5	<i>Limitation of Fa_{SS} Equation</i>	146
5.3.6	Interpretations of Fa Equations	146
5.3.7	Approximate Analytical Solution for Oral PK Model	147
5.4	Integration 2: Numerical Integration	147
5.4.1	Virtual Particle Bins	149
5.4.2	The Mass Balance of Dissolved Drug Amount in Each GI Position	149
5.4.3	Controlled Release of Virtual Particle Bin	150
5.5	<i>In Vivo</i> FA From PK Data	150
5.5.1	Absolute Bioavailability and Fa	151
5.5.2	Relative Bioavailability Between Solid and Solution Formulations	151
5.5.3	Relative Bioavailability Between Low and High Dose	152

5.5.4	Convolution and Deconvolution	152
5.5.4.1	<i>Convolution</i>	153
5.5.4.2	<i>Deconvolution</i>	154
5.6	Other Administration Routes	156
5.6.1	Skin	156
	References	157

6 PHYSIOLOGY OF GASTROINTESTINAL TRACT AND OTHER ADMINISTRATION SITES IN HUMANS AND ANIMALS 160

6.1	Morphology of Gastrointestinal Tract	160
6.1.1	Length and Tube Radius	160
6.1.2	Surface Area	161
6.1.2.1	<i>Small Intestine</i>	161
6.1.2.2	<i>Colon</i>	163
6.1.3	Degree of Flatness	164
6.1.3.1	<i>Small Intestine</i>	164
6.1.3.2	<i>Colon</i>	164
6.1.4	Epithelial Cells	165
6.1.4.1	<i>Apical and Basolateral Lipid Bilayer Membranes</i>	165
6.1.4.2	<i>Tight Junction</i>	168
6.1.4.3	<i>Mucous Layer</i>	168
6.2	Movement of the Gastrointestinal Tract	170
6.2.1	Transit Time	170
6.2.1.1	<i>Gastric Emptying Time (GET)</i>	170
6.2.1.2	<i>Small Intestinal Transit Time</i>	170
6.2.1.3	<i>Colon Transit Time</i>	171
6.2.2	Migrating Motor Complex	171
6.2.3	Agitation	173
6.2.3.1	<i>Mixing Pattern</i>	173
6.2.3.2	<i>Agitation Strength</i>	175
6.2.3.3	<i>Unstirred Water Layer on the Intestinal Wall</i>	176
6.3	Fluid Character of the Gastrointestinal Tract	178
6.3.1	Volume	178
6.3.1.1	<i>Stomach</i>	178
6.3.1.2	<i>Small Intestine</i>	178
6.3.1.3	<i>Colon</i>	179

6.3.2	Bulk Fluid pH and Buffer Concentration	179
	6.3.2.1 <i>Stomach</i>	181
	6.3.2.2 <i>Small Intestine</i>	181
	6.3.2.3 <i>Colon</i>	181
6.3.3	Microclimate pH	181
	6.3.3.1 <i>Small Intestine</i>	181
	6.3.3.2 <i>Colon</i>	182
6.3.4	Bile Micelles	182
	6.3.4.1 <i>Stomach</i>	183
	6.3.4.2 <i>Small Intestine</i>	183
	6.3.4.3 <i>Colon</i>	185
6.3.5	Enzymes and Bacteria	185
6.3.6	Viscosity, Osmolality, and Surface Tension	185
6.4	Transporters and Drug-Metabolizing Enzymes in the Intestine	186
	6.4.1 Absorptive Drug Transporters	186
	6.4.1.1 <i>PEP-T1</i>	186
	6.4.1.2 <i>OATP</i>	186
	6.4.2 Efflux Drug Transporters	186
	6.4.2.1 <i>P-gp</i>	186
	6.4.3 Drug-Metabolizing Enzymes	186
	6.4.3.1 <i>CYP3A4</i>	186
	6.4.3.2 <i>Glucuronyl Transferase and Sulfotransferase</i>	188
6.5	Intestinal and Liver Blood Flow	188
	6.5.1 Absorption Sites Connected to Portal Vein	188
	6.5.2 Villous Blood Flow (Q_{villi})	188
	6.5.3 Hepatic Blood Flow (Q_{h})	188
6.6	Physiology Related to Enterohepatic Recirculation	189
	6.6.1 Bile Secretion	189
	6.6.2 Mass Transfer into/from the Hepatocyte	190
	6.6.2.1 <i>Sinusoidal Membrane (Blood to Hepatocyte)</i>	190
	6.6.2.2 <i>Canalicular Membrane (Hepatocyte to Bile Duct)</i>	191
6.7	Nasal	191
6.8	Pulmonary	193
	6.8.1 Fluid in the Lung	193
	6.8.2 Mucociliary Clearance	193
	6.8.3 Absorption into the Circulation	194

6.9 Skin	194
References	196

7 DRUG PARAMETERS	206
7.1 Dissociation Constant (pK_a)	206
7.1.1 pH Titration	207
7.1.2 pH–UV Shift	207
7.1.3 Capillary Electrophoresis	207
7.1.4 pH–Solubility Profile	208
7.1.5 Calculation from Chemical Structure	208
7.1.6 Recommendation	208
7.2 Octanol–Water Partition Coefficient	208
7.2.1 Shake Flask Method	209
7.2.2 HPLC Method	210
7.2.3 Two-Phase Titration Method	210
7.2.4 PAMPA-Based Method	210
7.2.5 <i>In Silico</i> Method	210
7.2.6 Recommendation	210
7.3 Bile Micelle Partition Coefficient (K_{bm})	211
7.3.1 Calculation from Solubility in Biorelevant Media	211
7.3.2 Spectroscopic Method	212
7.3.3 Recommendations	212
7.4 Particle Size and Shape	212
7.4.1 Microscope	213
7.4.2 Laser Diffraction	215
7.4.3 Dynamic Laser Scattering (DLS)	215
7.4.4 Recommendations	215
7.5 Solid Form	215
7.5.1 Nomenclature	215
7.5.1.1 <i>Crystalline and Amorphous</i>	215
7.5.1.2 <i>Salts, Cocrystals, and Solvates</i>	216
7.5.1.3 <i>Hydrate</i>	217
7.5.2 Crystal Polymorph	217
7.5.2.1 <i>True Polymorph and Pseudopolymorph</i>	217
7.5.2.2 <i>Kinetic Resolution versus Stable Form</i>	217
7.5.2.3 <i>Dissolution Profile Advantages of Less Stable Forms</i>	218
7.5.2.4 <i>Enantiotropy</i>	218

7.5.3	Solid Form Characterization	219
7.5.3.1	<i>Polarized Light Microscopy (PLM)</i>	219
7.5.3.2	<i>Powder X-Ray Diffraction (PXRD)</i>	219
7.5.3.3	<i>Differential Scanning Calorimeter (DSC) and Thermal Gravity (TG)</i>	220
7.5.3.4	<i>High Throughput Solid Form Screening</i>	221
7.5.4	Wettability and Surface Free Energy	222
7.5.5	True Density	222
7.6	Solubility	223
7.6.1	Terminology	223
7.6.1.1	<i>Definition of Solubility</i>	223
7.6.1.2	<i>Intrinsic Solubility</i>	223
7.6.1.3	<i>Solubility in Media</i>	223
7.6.1.4	<i>Initial pH and Final pH</i>	224
7.6.1.5	<i>Supersaturable API</i>	224
7.6.1.6	<i>Critical Supersaturation Concentration and Induction Time</i>	224
7.6.1.7	<i>Dissolution Rate and Dissolution Profile</i>	225
7.6.2	Media	225
7.6.2.1	<i>Artificial Stomach Fluids</i>	225
7.6.2.2	<i>Artificial Small Intestinal Fluids</i>	225
7.6.3	Solubility Measurement	225
7.6.3.1	<i>Standard Shake Flask Method</i>	225
7.6.3.2	<i>Measurement from DMSO Sample Stock Solution</i>	227
7.6.3.3	<i>Solid Surface Solubility</i>	228
7.6.3.4	<i>Method for Nanoparticles</i>	228
7.6.4	Recommendation	228
7.6.4.1	<i>Early Drug Discovery Stage (HTS to Early Lead Optimization)</i>	229
7.6.4.2	<i>Late Lead Optimization Stage</i>	229
7.6.4.3	<i>Transition Stage between Discovery and Development</i>	229
7.7	Dissolution Rate/Release Rate	230
7.7.1	Intrinsic Dissolution Rate	230
7.7.2	Paddle Method	230
7.7.2.1	<i>Apparatus</i>	231
7.7.2.2	<i>Fluid Condition</i>	231
7.7.2.3	<i>Agitation</i>	232

7.7.3	Flow-Through Method	233
7.7.4	Multicompartment Dissolution System	233
7.7.5	Dissolution Permeation System	233
7.7.6	Recommendation	235
7.8	Precipitation	235
7.8.1	Kinetic pH Titration Method	235
7.8.2	Serial Dilution Method	236
7.8.3	Two-Chamber Transfer System	236
7.8.4	Nonsink Dissolution Test	236
7.9	Epithelial Membrane Permeability	240
7.9.1	Back-Estimation from $F_a\%$	241
7.9.2	<i>In Situ</i> Single-Pass Intestinal Perfusion	241
7.9.3	Cultured Cell Lines (Caco-2, MDCK, etc.)	243
7.9.4	PAMPA	244
7.9.5	Estimation of $P_{trans,0}$ from Experimental Apparent Membrane Permeability	246
7.9.6	Estimation of $P_{trans,0}$ from Experimental $\log P_{oct}$	247
7.9.7	Mechanistic Investigation	247
7.9.8	Limitation of Membrane Permeation Assays	247
	7.9.8.1 <i>UWL Adjacent to the Membrane</i>	249
	7.9.8.2 <i>Membrane Binding</i>	250
	7.9.8.3 <i>Low Solubility</i>	250
	7.9.8.4 <i>Differences in Paracellular Pathway</i>	251
	7.9.8.5 <i>Laboratory to Laboratory Variation</i>	251
	7.9.8.6 <i>Experimental Artifacts in Carrier-Mediated Membrane Transport</i>	251
7.9.9	Recommendation for P_{ep} and P_{eff} Estimation	251
	7.9.9.1 <i>Hydrophilic Drugs</i>	251
	7.9.9.2 <i>Lipophilic Drugs</i>	252
	7.9.9.3 <i>Drugs with Medium Lipophilicity</i>	252
7.10	<i>In Vivo</i> Experiments	252
7.10.1	P.O	252
7.10.2	I.V	253
7.10.3	Animal Species	253
7.10.4	Analysis	254
	References	254
8	VALIDATION OF MECHANISTIC MODELS	266
8.1	Concerns Related to Model Validation Using <i>In Vivo</i> Data	267

8.2	Strategy for Transparent and Robust Validation of Biopharmaceutical Modeling	267
8.3	Prediction Steps	268
8.4	Validation for Permeability-Limited Cases	279
8.4.1	Correlation Between Fa% and P_{eff} Data for Humans (Epithelial Membrane Permeability-Limited Cases PL-E)	279
8.4.2	Correlation Between <i>In Vitro</i> Permeability and P_{eff} and/or Fa% (PL-E Cases)	283
8.4.2.1	<i>Caco-2</i>	283
8.4.2.2	<i>PAMPA</i>	285
8.4.2.3	<i>Experimental log P_{oct} and pK_a</i>	285
8.4.3	P_{eff} for UWL Limited Cases	287
8.4.4	Chemical Structure to P_{eff} , Fa%, and <i>Caco-2</i> Permeability	288
8.5	Validation for Dissolution-Rate and Solubility-Permeability-Limited Cases (without the Stomach Effect)	290
8.5.1	Fa% Prediction Using <i>In Vitro</i> Dissolution Data	290
8.5.2	Fa% Prediction Using <i>In Vitro</i> Solubility and Permeability Data	292
8.6	Validation for Dissolution-Rate and Solubility-Permeability-Limited Cases (with the Stomach Effect)	305
8.6.1	Difference Between Free Base and Salts	305
8.6.2	Simulation Model for Free Base	305
8.6.3	Simulation Results	307
8.7	Salts	307
8.8	Reliability of Biopharmaceutical Modeling	311
	References	311
9	BIOEQUIVALENCE AND BIOPHARMACEUTICAL CLASSIFICATION SYSTEM	322
9.1	Bioequivalence	322
9.2	The History of BCS	324
9.3	Regulatory Biowaiver Scheme and BCS	326
9.3.1	Elucidation of BCS Criteria in Regulatory Biowaiver Scheme	327
9.3.1.1	<i>Congruent Condition of Bioequivalence</i>	328
9.3.1.2	<i>Equivalence of Dose Number (Do)</i>	329

9.3.1.3	<i>Equivalence of Permeation Number (Pn)</i>	329
9.3.1.4	<i>Equivalence of Dissolution Number (Dn)</i>	329
9.3.2	Possible Extension of the Biowaiver Scheme	331
9.3.2.1	<i>Dose Number Criteria</i>	331
9.3.2.2	<i>Permeability Criteria</i>	332
9.3.3	Another Interpretation of the Theory	332
9.3.3.1	<i>Another Assumption about Dissolution Test</i>	332
9.3.3.2	<i>Assessment of Suitability of Dissolution Test Based on Rate-Limiting Process</i>	333
9.3.4	Validation of Biowaiver Scheme by Clinical BE Data	333
9.3.5	Summary for Regulatory BCS Biowaiver Scheme	334
9.4	Exploratory BCS	335
9.5	<i>In Vitro–In Vivo</i> Correlation	335
9.5.1	Levels of IVIVC	335
9.5.2	Judgment of Similarity Between Two Formulations (f ₂ Function)	336
9.5.3	Modeling the Relationship Between f ₂ and Bioequivalence	336
9.5.4	Point-to-Point IVIVC	337
	References	338
10	DOSE AND PARTICLE SIZE DEPENDENCY	340
10.1	Definitions and Causes of Dose Nonproportionality	340
10.2	Estimation of the Dose and Particle Size Effects	341
10.2.1	Permeability-Limited Cases (PL)	341
10.2.2	Dissolution-Rate-Limited (DRL) Cases	341
10.2.3	Solubility–Epithelial Membrane Permeability Limited (SL-E) Cases	342
10.2.4	Solubility-UWL-Permeability-Limited Cases	344
10.3	Effect of Transporters	344
10.4	Analysis of <i>In Vivo</i> Data	345
	References	346
11	ENABLING FORMULATIONS	347
11.1	Salts and Cocrystals: Supersaturating API	347
11.1.1	Scenarios of Oral Absorption of Salt	349
11.1.2	Examples	350

11.1.2.1	<i>Example 1: Salt of Basic Drugs</i>	350
11.1.2.2	<i>Example 2: Salt of Acid Drugs</i>	352
11.1.2.3	<i>Example 3: Other Supersaturable API Forms</i>	353
11.1.3	Suitable Drug for Salts	353
11.1.3.1	<i>pK_a Range</i>	353
11.1.3.2	<i>Supersaturability of Drugs</i>	355
11.1.4	Biopharmaceutical Modeling of Supersaturable API Forms	357
11.2	Nanomilled API Particles	358
11.3	Self-Emulsifying Drug Delivery Systems (Micelle/Emulsion Solubilization)	360
11.4	Solid Dispersion	363
11.5	Supersaturable Formulations	364
11.6	Prodrugs to Increase Solubility	365
11.7	Prodrugs to Increase Permeability	365
11.7.1	Increasing Passive Permeation	366
11.7.2	Hitchhiking the Carrier	366
11.8	Controlled Release	366
11.8.1	Fundamentals of CR Modeling	367
11.8.2	Simple Convolution Method	368
11.8.3	Advanced Controlled-Release Modeling	368
11.8.4	Controlled-Release Function	368
11.8.5	Sustained Release	368
11.8.5.1	<i>Objectives to Develop a Sustained-Release Formulation</i>	368
11.8.5.2	<i>Suitable Drug Character for Sustained Release</i>	369
11.8.5.3	<i>Gastroretentive Formulation</i>	369
11.8.6	Triggered Release	369
11.8.6.1	<i>Time-Triggered Release</i>	369
11.8.6.2	<i>pH-Triggered Release</i>	369
11.8.6.3	<i>Position-Triggered Release</i>	371
11.9	Communication with Therapeutic Project Team	371
	References	373

12 FOOD EFFECT 379

12.1	Physiological Changes Caused by Food	379
12.1.1	Food Component	380

12.1.2	Fruit Juice Components	380
12.1.3	Alcohol	382
12.2	Types of Food Effects and Relevant Parameters in Biopharmaceutical Modeling	382
12.2.1	Delay in T_{\max} and Decrease in C_{\max}	382
12.2.2	Positive Food Effect	383
	12.2.2.1 <i>Bile Micelle Solubilization</i>	383
	12.2.2.2 <i>Increase in Hepatic Blood Flow</i>	388
	12.2.2.3 <i>Increase in Intestinal Blood Flow</i>	388
	12.2.2.4 <i>Inhibition of Efflux Transporter and Gut Wall Metabolism</i>	389
	12.2.2.5 <i>Desaturation of Influx Transporter</i>	391
12.2.3	Negative Food Effect	391
	12.2.3.1 <i>Bile Micelle Binding/Food Component Binding</i>	391
	12.2.3.2 <i>Inhibition of Uptake Transporter</i>	392
	12.2.3.3 <i>Desaturation of First-Pass Metabolism and Efflux Transport</i>	394
	12.2.3.4 <i>Viscosity</i>	398
	12.2.3.5 <i>pH Change in the Stomach</i>	398
	12.2.3.6 <i>pH Change in the Small Intestine</i>	398
12.3	Effect of Food Type	398
12.4	Biopharmaceutical Modeling of Food Effect	401
12.4.1	Simple Flowchart and Semiquantitative Prediction	401
12.4.2	More Complicated Cases	402
	References	403
13	BIOPHARMACEUTICAL MODELING FOR MISCELLANEOUS CASES	412
13.1	Stomach pH Effect on Solubility and Dissolution Rate	412
13.1.1	Free Bases	413
13.1.2	Free Acids and Undissociable Drugs	413
13.1.3	Salts	413
13.1.4	Chemical and Enzymatic Degradation in the Stomach and Intestine	413
13.2	Intestinal First-Pass Metabolism	414
13.3	Transit Time Effect	415
13.3.1	Gastric Emptying Time	415
13.3.2	Intestinal Transit Time	415

13.4	Other Chemical and Physical Drug–Drug Interactions	415
13.4.1	Metal Ions	415
13.4.2	Cationic Resins	416
13.5	Species Difference	417
13.5.1	Permeability	417
13.5.2	Solubility/Dissolution	418
13.5.3	First-Pass Metabolism	419
13.6	Validation of GI Site-Specific Absorption Models	421
13.6.1	Stomach	421
13.6.2	Colon	422
13.6.3	Regional Difference in the Small Intestine: Fact or Myth?	422
	13.6.3.1 <i>Transporter</i>	422
	13.6.3.2 <i>Bile-Micelle Binding and Bimodal Peak Phenomena</i>	422
	References	426
14	INTESTINAL TRANSPORTERS	430
14.1	Apical Influx Transporters	431
14.1.1	Case Example 1: Antibiotics	431
14.1.2	Case Example 2: Valacyclovir	433
14.1.3	Case Example: Gabapentin	434
14.2	Efflux Transporters	435
14.2.1	Effect of P-gp	435
14.2.2	Drug–Drug Interaction (DDI) via P-gp	437
14.3	Dual Substrates	438
14.3.1	Talinolol	438
14.3.2	Fexofenadine	441
14.4	Difficulties in Simulating Carrier-Mediated Transport	442
14.4.1	Absorptive Transporters	442
	14.4.1.1 <i>Discrepancies Between In Vitro and In Vivo K_m Values</i>	442
	14.4.1.2 <i>Contribution of Other Pathways</i>	443
14.4.2	Efflux Transporters	443
14.5	Summary	445
	References	446
15	STRATEGY IN DRUG DISCOVERY AND DEVELOPMENT	452
15.1	Library Design	452

15.2	Lead Optimization	453
15.3	Compound Selection	455
15.4	API Form Selection	455
15.5	Formulation Selection	455
15.6	Strategy to Predict Human Fa%	456
	References	457
16	EPISTEMOLOGY OF BIOPHARMACEUTICAL MODELING AND GOOD SIMULATION PRACTICE	459
16.1	Can Simulation be so Perfect?	459
16.2	Parameter Fitting	460
16.3	Good Simulation Practice	461
	16.3.1 Completeness	461
	16.3.2 Comprehensiveness	462
	References	463
	APPENDIX A GENERAL TERMINOLOGY	464
A.1	Biopharmaceutic	464
A.2	Bioavailability (BA% or F)	464
A.3	Drug Disposition	465
A.4	Fraction of a Dose Absorbed (Fa)	465
A.5	Modeling/Simulation/ <i>In Silico</i>	465
A.6	Active Pharmaceutical Ingredient (API)	465
A.7	Drug Product	465
A.8	Lipophilicity	465
A.9	Acid and Base	466
A.10	Solubility	466
A.11	Molecular Weight (MW)	466
A.12	Permeability of a Drug	466
	APPENDIX B FLUID DYNAMICS	468
B.1	Navier–Stokes Equation and Reynolds Number	468
B.2	Boundary Layer Approximation	469
B.3	The Boundary Layer and Mass Transfer	470
B.4	The Thickness of the Boundary Layer	470
	B.4.1 99% of Main Flow Speed	471
	B.4.2 Displacement Thickness	471
	B.4.3 Momentum Thickness	471
B.5	Sherwood Number	471

B.6	Turbulence	473
B.7	Formation of Eddies	474
B.8	Computational Fluid Dynamics	474
	References	476

INDEX	477
--------------	------------

PREFACE

“Science is built of facts the way a house is built of bricks; but an accumulation of facts is no more science than a pile of bricks is a house.”

—Henry Poincare

The aim of this book is to provide a systematic understanding of biopharmaceutical modeling. Probably, this is the first book challenging this difficult task.

Biopharmaceutical modeling demands a wide range of knowledge. We need to understand the physical theories, the physiology of the gastrointestinal tract, and the meaning of drug parameters. This book covers the wide range of scientific topics required to appropriately perform and evaluate biopharmaceutical modeling. In this book, oral absorption of a drug is mainly discussed. However, the same scientific framework is applicable for other administration routes such as nasal and pulmonary administrations.

Oral absorption of a drug is a complex process that consists of dissolution, precipitation, intestinal wall permeation, and gastrointestinal transit. In addition, drug metabolism can also occur in the intestinal wall and the liver before drug molecules enter into systemic circulation.

Historically, a reductionist approach has been taken to understand the oral absorption of a drug. Each process of oral absorption was reduced to its subprocesses up to the molecular level. However, understanding each piece of the puzzle is insufficient in understanding the whole picture of oral absorption. It is critically important to reconstruct the whole process of oral absorption and understand the interrelationship between each piece that comprises oral absorption of a drug.

In the field of biology, computational systems biology has been emerging since the millennium [1]. In systems biology, the interactions between biological molecules are investigated in both reductionist and constitutive approaches to

understand the quantitative relationship between a disease state and each molecular process. In this book, a similar approach is applied for the oral absorption of a drug.

In the first section of this book, the whole picture of oral absorption is discussed. As the central dogma of oral drug absorption, the interplay of dissolution rate, solubility, and permeability of a drug is discussed in a comprehensive manner without using mathematics. Even though the discussion in the first section is only a conceptual and qualitative outline, correct understanding of this central dogma will be of great benefit for drug discovery and development. The central dogma of oral drug absorption is the basis of the biopharmaceutical classification system (BCS), which is widely used in drug discovery and development [2].

We then move forward to each theory that comprises the entire oral absorption model. In this book, the entire mathematical framework is called the “gastrointestinal unified theoretical framework (GUT framework).” The concept of “concentration” is first discussed in detail, as it is critically important for understanding biopharmaceutical modeling. Then, theories of solubility, dissolution, precipitation, membrane permeation, and drug metabolisms are discussed. Each theory is described based on the unified definition of drug concentration and then incorporated into the GUT framework.

We then move forward to the physiological and drug property data that is used for biopharmaceutical modeling. The quality of biopharmaceutical modeling heavily relies on the quality of input data. The input data are roughly categorized into drug property and physiological parameters. These data are reviewed from the viewpoint of their use in biopharmaceutical modeling.

Before moving on to the discussions about practical applications of biopharmaceutical modeling in drug research, the validity of biopharmaceutical modeling is critically reviewed. A step-by-step approach has been taken to validate the biopharmaceutical modeling employing Occam’s razor as a leading principle.

As the applications of biopharmaceutical modeling in drug research, biopharmaceutical classification system, dose/particle size dependency prediction, selection of solid form and enabling formulation, food effect prediction, etc. are then discussed.

Next, the strategy to use biopharmaceutical modeling in drug research and regulatory application is discussed. Introduction of good simulation practice for biopharmaceutical modeling would be an emergent issue for regulatory application.

Many figures and tables are provided to make it easy to understand biopharmaceutical modeling. In addition, more than 900 references are cited. I hope that readers will enjoy reading this book and that this book will be a helpful reference for biopharmaceutical modeling.

I would like to thank Mr. Jonathan Rose of John Wiley & Sons, Inc. for giving me this opportunity to write a book about biopharmaceutical modeling.

I would like to thank Dr. Takashi Mano and Dr. Ravi Shanker for carefully reading my manuscript and giving me valuable advice. They also supported the investigation of biopharmaceutical modeling at Pfizer. I also thank Dr. Brian

Henry, Dr. Mark McAllister, and Ms. Nicola Clear for their kind support at Pfizer. The scientific discussion with the Pfizer biopharmaceutics group members improved my understanding of this subject. The suggestions from Prof. Steve Sutton, Dr. Kazuko Sagawa, and Ms. Kelly Jones about *in vivo* physiology are greatly appreciated. Ms. Joanne Bennett kindly lectured me about the cell culture models. I would like to thank Dr. Claudia da Costa Mathews, Dr. Hannah Pearce, Dr. Sue Mei Wong, Mr. Simon Pegg, Mr. Neil Flanagan, Mr. Mike Cram, Mr. Unai Vivanco, Ms. Sonia Patel, and Mr. Richard Manley for investigating the enabling formulations and physchem screening. I would like to thank the Pfizer Pharmaceutical Science members for supporting and inspiring me to pursue the sciences and practical drug research work. I would like to thank Dr. Tomomi Mastuura for her instructions about pharmacokinetics. I would like to thank Dr. Stefan Steyn for implementation of biopharmaceutical modeling in early drug discovery.

Thanks also goes to the Pfizer Nagoya Pharm R&D members. Mr. Shohei Sugimoto, Dr. Toshiyuki Niwa, Dr. Naofumi Hashimoto, Mr. Akinori Ito, Dr. Takashi Kojima, Mr. Omura Atsushi, and Mr. Morimichi Sato kindly taught me solid-state chemistry and enabling formulations. I would like to thank Mr. Arimich Okazaki, Mr. Yohei Kawabata, Ms. Keiko Kako, Dr. Sumitra Tavornvipas, Ms. Akiko Suzuki, Ms. Tomoko Matsuda, and Ms. Shiho Torii for kindly working together toward progress of the science at the Nagoya site.

I would like to thank Dr. Ryusuke Takano of Chugai Pharm. for his excellent works on biopharmaceutical sciences. I also would like to thank the Chugai physicochemical and pharmacokinetics group members, especially Mr. Hirokazu Hamada, Dr. Noriyuki Takata, Dr. Akiko Koga, Mr. Ken Goshi, Dr. Kazuya Nakagomi, Mr. Ro Irisawa, Ms. Harumi Onoda, Dr. Hidetoshi Ushio, Dr. Yoshiaki Hayashi, Dr. Yoshiaki Nabuchi, Dr. Minoru Machida, and Dr. Ryoichi Saito. They brought me up as an industrial scientist. I would like to thank Dr. Ken-ichi Sakai and Mr. Kouki Obata for working with me toward progress of the sciences at Chugai.

I would like to thank Dr. Alex Avdeef for finding a young scientist at a rural countryside in Japan and introducing him to the world. I greatly appreciate the kind support from the UK physicochemical scientist community, especially, Dr. John Comer, Dr. Karl Box, Dr. Alan Hill, Dr. Nicola Colclough, Dr. Toni Llinas, Dr. Darren Edwards, and other scientists. Their kind support made my UK life enjoyable and fruitful. I would also like to thank Prof. Amin Rostami-hochaghan, Dr. David Turner, Dr. Sibylle Neuhoff, and Dr. Jamai Masoud of SimCYP. I would like to thank Prof. Per Artursson, Dr. Manfred Kansy, Dr. Bernard Faller, Dr. Edward Kerns, and Dr. Li Di for discussions about PAMPA. I would like to thank Dr. Lennart Lindfors for constructive discussions.

I greatly appreciate the mentorship of Prof. Katsuhide Terada and Prof. Shinji Yamashita. I also would like to thank Dr. Makoto Kataoka and Dr. Yoshie Masaoka for the collaboration works.

Finally, I would like to express my greatest thanks to my wife, Hitomi. Without her dedicated support, I could not have gone through the tough task of writing a book like this. I sincerely dedicate this book to her.

KIYO SUGANO

REFERENCES

1. Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of *in vitro* drug product dissolution and *in vivo* bioavailability. *Pharm. Res.*, 12, 413–420.
2. Kitano, H. (2002). Computational systems biology. *Nature*, 420, 206–210.

LIST OF ABBREVIATIONS

API	Active pharmaceutical ingredient
A to B	Apical-to-basal
BA	Absolute bioavailability
BCS	Biopharmaceutical classification system
B to A	Basal-to-apical
CER	Ceramide
CFD	Computational fluid dynamics
CHO	Cholesterol
CM	Carrier mediated
CNT	Classical nucleation theory
CSSR	Critical supersaturation ratio
DDI	Drug–drug interaction
DRL	Dissolution-rate limited
DSC	Differential scanning calorimeter
DTA	Differential thermal analysis
FFA	Free fatty acid
FaSSIF	Fasted stated simulated intestinal fluid
FeSSIF	Fed stated simulated intestinal fluid
FIH	First in human
GET	Gastric emptying time
GI	Gastrointestinal
GUT framework	Gastrointestinal unified theoretical framework
HH	Henderson–Hasselbalch
IVIVC	<i>In vitro</i> (dissolution)– <i>in vivo</i> correlation
LCT	Long-chain triglyceride
LHS	Left-hand side

MCT	Medium chain triglyceride
MMC	Migrating motor complex
NBE	Nernst–Brunner equation
NS	Navier–Stokes
PAMPA	Parallel artificial membrane permeation assay
PC	Phosphatidylcholine
PDE	Particle drifting effect
PE	Phosphatidylethanolamine
PG	Phosphatidylglycerol
PI	Phosphatidylinositol
PK	Pharmacokinetics
PL	Permeability limited
PLM	Polarized light microscopy
PPS	Prediction process step
PS	Phosphatidylserine
PXRD	Powder X-ray diffraction
RHS	Right-hand side
RPM	Revolution per minute
SC	Stratum corneum
SEDDS	Self-emulsifying drug delivery system
SITT	Small intestinal transit time
SL-E	Solubility–epithelial membrane permeability limited
SL-U	Solubility–UWL permeability limited
SPIP	Single-pass intestinal perfusion
TC	Taurocholic acid
TG	Thermal gravity
USP	United state pharmacopeia
UWL	Unstirred water layer
A_H	Hydrogen-donor strength
AUC	Area under the curve (subscript indicates administration route, etc.)
$A_{\text{blood vessel}}$	Surface area of the blood vessel in the villi
Acc	Accessibility to villi surface
C_D	resistance coefficient
CF_{SSR}	Steady-state reduction correction factor
CL_h	Hepatic clearance
$CL_{h,int}$	Intrinsic hepatic clearance
CL_{perm}	Permeation clearance
$CL_{\text{subepithelial}}$	Permeation clearance of subepithelial space
CL_{tot}	Total clearance
CR	Controlled-release function
C_{active}	Effective concentration for active transport
C_{bile}	Concentration of bile acid
C_{bm}	Concentration of bile-micelle bound drug

C_{dissolv}	Dissolved drug concentration
$C_{\text{dissolv,ss}}$	Steady-state concentration
C_{nc}	Number of critical cluster per volume
C_{p}	Plasma concentration
C_{pd}	Particle-drifting coefficient
$C_{\text{subepithelial}}$	Concentration of drug in subepithelial space
C_{tot}	Total drug concentration
$C_{\text{u,z}}$	Concentration of unbound drug with charge z
C_{water}	Concentration of water (55.6 M)
DF	Degree of flatness of intestinal tube
D_{albumin}	Diffusion coefficient of albumin-bound drug
D_{bm}	Diffusion coefficient of bile-micelle-bound drug
D_{eff}	Effective diffusion coefficient
Disp	Dispersion coefficient for GI transit
$D_{\text{m}}(x)$	Local diffusion coefficient at position x in membrane
D_{mono}	Diffusion coefficient of monomer drug
Dn	Dissolution number
Do	Dose number
D_{oct}	Octanol–water distribution coefficient
Dose	Dose amount (subscript indicates administration route, etc.)
D_{paddle}	Paddle diameter
D_{vessel}	Diameter of vessel
F	Absolute bioavailability
Fa	Fraction of a dose absorbed (subscript indicates administration route, etc.)
Fa _{DRL}	Fa for the dissolution-rate-limited cases
Fa _{NI}	Fa calculated by numerical integration using the S1I7C1 model
Fa _{PL}	Fa for the permeability-limited cases
Fa _{SL}	Fa for the solubility-permeability-limited cases
Fa _{SS}	Fa calculated with steady-state approximation
Fa _{min. limit}	Minimum value of Fa _{PL} , Fa _{SL} , and Fa _{DRL}
Fa _{sfo}	Fa calculated as sequential first-order processes of dissolution and permeation
F_{cn}	Frequency of addition of another molecule to critical cluster
Fg	Fraction not metabolized in intestinal epithelial cells
Fh	Fraction not metabolized in hepatic first pass
GIP	Position in GI tract
Gz	Graetz number
H_{paddle}	Height of paddle from vessel bottom
H_{villi}	Height of villi
J_{max}	Maximum flux by carrier-mediated transport
J_{nc}	Primary nucleation rate per volume per time
J_{perm}	Permeation flux

K_a	Dissociation constant
K_{bm}	Bile micelles–water partition coefficient
K_m	Michaelis–Menten constant
$K_{org}(x)$	Local partition coefficient at position x in membrane
K_{sc}	Partition coefficient into stratum corneum
K_{sp}	Solubility product
K_w	Ionic product for water
$K_{transit,k}$	First-order transition kinetic constant
L	Representative length
L_{GI}	Length of GI tract
N_A	Avogadro number
$N_{API,GI,k}$	Number of API particle bins in GI position k
N_n	Number of nuclei
N_p	Number of particles in one dose
P_{CM}	Carrier-mediated transcellular permeability
PE	Plicate expansion
P_{UWL}	UWL permeability in the GI tract
P_{WC}	Permeability by water conveyance
P_{app}	Apparent permeability of <i>in vitro</i> membrane permeation assay
P_{eff}	Effective intestinal membrane permeability
P_{ep}	Epithelial membrane permeability
P_{oct}	Octanol–water partition coefficient
P_{para}	Paracellular pathway permeability
$P_{plicate}$	Plicate surface permeability
P_{trans}	Transcellular pathway permeability
$P_{trans,0}$	Intrinsic transcellular pathway permeability of undissociated species
Q_{GI}	Flow rate along small intestine
Q_h	Hepatic blood flow
Q_{villi}	Villi blood flow
Q_{in}	Infusion rate
R_{GI}	Radius of GI tract
RK	Renkin function
R_{MW}	Apparent pore radius of paracellular pathway based on MW selectivity
RPM_{min}	Minimum agitation speed
R_{SA}	Ratio of drug particle surface area in UWL and villi surface area
Re	Reynolds number
R_{mucus}	Nominal pore radius of mucus layer
R_{para}	Apparent pore radius of the paracellular pathway
S_0	Intrinsic solubility of undissociated drug
$S_{0,rp}$	Solubility of particles with radius r_p

$S_{0,\infty}$	Solubility of particles with infinitely large particle size
SA_{API}	Particle surface area of API
SA_{GI}	GI surface area for absorption (based on smooth tube)
SA_p	Surface area for one particle
SRn	Steady state reduction number
S_{blank}	Solubility in a blank buffer (without micelles)
Sc	Schmitt number
$S_{cocystal}$	Intrinsic solubility of cocystal
$S_{dissolv}$	Solubility in a biorelevant media (unbound + micelle bound)
Sh	Sherwood number
Sh_{disk}	Sherwood number for rotating disk
Sh_p	Sherwood number for particle
Sh_{tube}	Sherwood number for tube
$Sn_{T_{si}}$	Saturation number at time T_{si}
Sn_{ini}	Initial saturation number (Sn_{ini})
S_{salt}	Intrinsic solubility of salt
$S_{surface}$	Solubility at solid surface
T_{DO1}	Time when drug amount remaining in small intestine gives Do = 1
T_m	Melting point (Kelvin)
Tn_{exss}	Extended steady-state duration number
U	Flow speed
U_e	Microeddy effect velocity
Ur	Urinary excretion fraction
$U_{rel,tot}$	Relative flow velocity
U_t	Terminal sedimentation velocity
VE	Villi expansion
V_{GI}	GI fluid volume
V_c	Velocity of intestinal fluid
V_{me}	Velocity representing microeddy effect
V_p	Volume of one particle
V_{rel}	Relative velocity between fluid and particle
V_t	Terminal (sedimentation) slip velocity
V_X	McGowans molecular volume
$W_{channel}$	Width of channel between villi
W_{villi}	Width of villi
X_{bm}	Bile-micelle-bound drug amount
$X_{dissolv}$	Dissolved drug amount
$X_{u,z}$	Amount of unbound drug with charge z
Z_{ch}	Zel'dovich number
Z_{para}	Paracellular pathway charge
d_{disk}	Disk diameter
d_p	Particle diameter

d_{tube}	Tube diameter
f_{PSB}	Volume percentage of each particle size bin in one dose
f_{bm}	Fraction of bile-micelle-bound molecule
f_{n}, f_0	Fraction of undissociated species
$f_{\text{subepithelial}}$	Unbound fraction of drug in subepithelial space
f_{u}	Bile-micelle-unbound fraction
f_{up}	Plasma unbound fraction
f_z	Fraction of charged species
g	Gravitational acceleration constant
h	Unstirred water layer thickness
h_{HJ}	Criteria value for Hintz–Johnson model
h_{UWL}	Unstirred water layer thickness in the intestine
h_{WF}	Criteria value for Wang–Flanagan model
h_{fam}	Thickness of firmly adhered mucus layer
$h_{\text{UWL} \text{ vitro}}$	UWL thickness in <i>in vitro</i> permeability assay
$h_{\text{subepithelial}}$	Thickness of subepithelial space
k_{B}	Boltzmann constant
k_{abs}	Absorption rate coefficient
k_{deg}	Degradation rate constant
k_{diss}	Dissolution rate coefficient
k_{el}	Elimination rate
k_{mass}	Mass transfer coefficient
k_{perm}	Permeation rate coefficient
l_{tube}	Tube length
m.p.	Melting point (Celsius)
m_{atom}	Number of atoms in molecule
r_{mono}	Molecular radius
r_{p}	Particle radius (at time t)
$r_{\text{p,PSB}}$	Particle radius for particle size bin
$r_{\text{p,ini}}$	Initial particle radius
$r_{\text{p,ini,PSB}}$	Initial particle radius for particle size bin
$r_{\text{p,nc}}$	Critical radius of nuclei
v_{atom}	Relative volume of atom
v_{m}	Molecular volume
z	Molecular charge
ΔC	Concentration gradient
ΔG_{nc}	Energy barrier for nucleation
ΔH_{m}	Enthalpy of melting
ΔS_{f}	Entropy of fusion
ΔS_{m}	Entropy of melting
Π	Particle shape factor
β	Lump constant (β) of foreign particle number, sticking provability, etc
γ	Interfacial tension between solid surface and fluid

ε	Agitation strength (Energy input per time)
η	Kolmogorov's minimum eddy scale
λ_{disso}	Dissociation resistance from solid surface (in length dimension)
λ_{nc}	Interfacial attachment resistance (in length dimension)
μ	Viscosity of fluid
ν	Kinematic viscosity of fluid
ρ_f	Density of fluid
ρ_p	True density of drug
ψ_{cn}	Interfacial reaction rate correction factor